| 2020-RAMA-68859 | |
| Researchers at Purdue University have developed new drug candidates to treat Methicillin-resistant Staphylococcus aureus (MRSA)-related bacterial infection. MRSA-related infections are reaching a level of critical concern according to the Centers for Disease Control and Prevention. Purdue researchers have synthesized a line of 187 potential drug candidates, several of which exhibit excellent antimicrobial activity. Through in vitro against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (VRE), or Streptococcus pneumoniae in a human skin cells infection model, the new drug candidates showed no signs of cytotoxicity, and the skin cells maintained viability between 65-100%. Purdue researchers optimized these new antibacterial drug candidates and achieved a minimum inhibitory concentration between 3.0-5.2 micromolar against different bacterial strains and eliminated 98-99% of bacteria in two hours whereas the current treatment, vancomycin, requires twelve hours. Advantages -Fast-Acting -Effective Against Drug Resistant Bacterial Strains -Safe in Mammalian Cells Potential Applications -Pharmaceutics -Antibacterial Drug Development -Antibiotics Recent Publication: "Beta-,gamma-Diaryl alpha-methylene-gamma-butyrolactones as potent antibacterials against methicillin-resistant Staphylococcus aureus" Elsevier Journal of Bioorganic Chemistry DOI: 10.1016/j.bioorg.2020.104183 |
|
|
|
|
Apr 2, 2021
Utility Patent
United States
(None)
(None)
Apr 9, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
